Generalized status epilepticus possibly induced by gatifloxacin

Koussa, Salam; Samaha, Elia; Riachi, Moussa

doi:10.1111/j.1468-1331.2006.01250.x

Cited by 11 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Numerous case reports on the association between FQs and seizure have also been published. [2][3][4][5][6][7][8][9][10][11] Concerns were raised about the safety of FQs on the central nervous system. Although some studies have explored the potential mechanisms of FQ-induced seizure, [12][13][14][15] comprehensive epidemiologic data from populationbased studies are needed.…”

mentioning

confidence: 99%

Association between oral fluoroquinolones and seizures

Chui¹,

Chan²,

Wong³

et al. 2016

Neurology

View full text Add to dashboard Cite

Objectives: The aim of this study was to investigate the association and to estimate the crude absolute risk of seizure among patients exposed to fluoroquinolones (FQs) in Hong Kong and the United Kingdom.Methods: A self-controlled case series study was conducted. Data were collected from the Hong Kong Clinical Data Analysis and Reporting System database and the Clinical Practice Research Datalink. Patients who were prescribed any oral FQ and had an incident seizure diagnosis from 2001 to 2013 were included. The risk windows were defined as pre-FQ start, FQ-exposed, and post-FQ completion. Incidence rate ratios were estimated in all risk windows and compared with baseline periods. A post hoc subgroup analysis was conducted to examine the effect of patients with a history of seizure.Results: An increased incidence rate ratio was found in the pre-FQ start periods and no association was found in the post-FQ completion periods in both databases. The crude absolute risk of an incident seizure in 10,000 oral FQ prescriptions was 0.72 (95% confidence interval 0.47-1.10) in the Clinical Data Analysis and Reporting System and 0.40 (95% confidence interval 0.30-0.54) in the Clinical Practice Research Datalink. The rate ratio during treatment was not higher than pre-FQ start periods among patients with a history of seizure, therefore the results did not raise serious concerns.Conclusions: This study does not support a causal association between the use of oral FQs and the subsequent occurrence of seizure. An increased risk before the FQ exposure period suggests that the clinical indication for which FQ was prescribed may have contributed to the development of seizure rather than the drug itself.

show abstract

mentioning

confidence: 99%

Association between oral fluoroquinolones and seizures

Chui¹,

Chan²,

Wong³

et al. 2016

Neurology

View full text Add to dashboard Cite

show abstract

“…NCSE can manifest with various atypical symptoms that may result in misdiagnoses and delay proper treatment. [11][12][13] While NCSE has been associated with various medical and neurological disorders such as metabolic disturbances, structural brain diseases, autoimmune diseases, drugs, and drug withdrawal, [14][15][16][17][18] the exact causes of NCSE remain unclear in many cases. 11 Many of our patients with kidney disorders, especially those with acute kidney injury, developed NCSE and experienced poor outcomes.…”

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics and Treatment Outcomes of De Novo Nonconvulsive Status Epilepticus: A Retrospective Study

Lee

Park

et al. 2021

J Clin Neurol

View full text Add to dashboard Cite

Background and Purpose Nonconvulsive status epilepticus (NCSE) is challenging to diagnose. This study aimed to describe and classify the clinical features and electroencephalography (EEG) findings of patients with de novo NCSE and to correlate them with clinical outcomes. Methods We retrospectively reviewed the medical and EEG records of patients admitted to our institution with altered mentation and EEG abnormalities from January 1, 2013 to December 31, 2018. We evaluated premorbid modified Rankin Scale (mRS) scores, underlying disorders, precipitating factors, clinical manifestations, laboratory tests, and outcomes after a 3-month follow-up. Patients who met the Salzburg Consensus Criteria for NCSE were categorized into good-outcome and poor-outcome groups. A good outcome was defined as 1) clinical and electrographic seizures ceasing after treatment, and 2) an mRS score of ≤2 or remaining unchanged during the 3-month follow-up. A poor outcome was defined as 1) death, 2) seizures continuing despite treatment, or 3) a follow-up mRS score of ≥3 in a patient with a premorbid mRS score of ≤2, or a follow-up mRS score that increased in a patient with a premorbid mRS score of ≥3. Results The 48 included patients comprised 37 categorized into the good-outcome group and 11 into the poor-outcome group. The presence of acute metabolic disturbances was significantly correlated with poor outcome ( p =0.036), while the other analyzed variables were not significantly correlated with outcomes. Conclusions Acute metabolic disturbances in NCSE are associated with poor outcomes. Adequate treatment of underlying reversible disorders alongside controlling seizures is critical for patients with NCSE.

show abstract

“…4 Levofloxacin, ofloxacin, and moxifloxacin have the lowest reported frequencies of CNS toxicities of the fluoroquinolones. [5][6][7][8][9] Approximately 1.6% of FDA Adverse Events Reporting System reports for moxifloxacin include a reaction term of convulsions (Raisch DW, College of Pharmacy, University of New Mexico, personal communica-tion, 2013 Jun). [5][6][7][8][9] Approximately 1.6% of FDA Adverse Events Reporting System reports for moxifloxacin include a reaction term of convulsions (Raisch DW, College of Pharmacy, University of New Mexico, personal communica-tion, 2013 Jun).…”

Section: Continued On Page 912mentioning

confidence: 99%

“…2 Seizures have been associated with gatifloxacin, levofloxacin, and ofloxacin. 2,[5][6][7][8][9][10] There is one case report of seizures with moxifloxacin, though the patient was diagnosed with epilepsy before the incident. Although uncommon in the clinical efficacy trials, there are postmarketing reports of fluoroquinolones causing CNS effects including seizures and convulsions.…”

Section: Continued On Page 912mentioning

confidence: 99%